Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring hypertension, systolic blood pressure, exercise test, cardiovascular disease, aliskiren, valsartan
Eligibility Criteria
Inclusion criteria:
- Mean sitting systolic blood pressure ≥ 140 mmHg and < 180 mmHg measured at rest
- Patients able to exercise and to reach 85% of their predicted heart rate during a standard exercise test on a treadmill according to the Bruce Protocol
Exclusion criteria:
- Patients not confident in exercising or not able to exercise
- Absolute contraindication to exercise
- Mean sitting systolic blood pressure ≥ 180 mmHg and/or mean sitting diastolic blood pressure ≥ 110 mmHg measured at rest
Other protocol-defined inclusion/exclusion criteria applied to the study.
Sites / Locations
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Aliskiren
Valsartan
For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).